Antibody Drug Conjugates

© Getty Images

ADC licensing deals reached peak of $16.6 billion in 2022

By Isabel Cameron

The biopharmaceutical industry witnessed a 400% growth in total deal value of antibody-drug conjugate (ADC) licensing agreements from 2017-2022 and reached a peak of $16.6 billion in 2022, reveals data and analytics company GlobalData.

© Getty Images

SOTIO expands ADC pipeline with Synaffix tie up

By Isabel Cameron

Synaffix, a Lonza company commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has entered a licensing agreement with SOTIO, a clinical stage immuno-oncology company owned by PPF Group.

© Getty Images

ImmunoGen to develop next-generation ADCs with ImmunoBiochem

By Isabel Cameron

ImmunoGen, a biotech company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer, has announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem, a biopharma firm...


Samsung Ventures invests in Araris Biotech in emerging ADC strategy

By Jonathan Smith

Samsung Ventures, the global investment arm of Samsung Group, has invested an undisclosed amount in the Swiss company Araris Biotech. The deal is independent from Araris’ ongoing Series A fundraising and will be used to bankroll the development of antibody-drug...


Follow us


View more

Featured Suppliers